A nucleoside is an organic molecule composed of a nitrogenous base covalently linked to a five-carbon sugar, either ribose or 2'-deoxyribose, through an N-glycosidic bond at the 1' position of the sugar and the N9 of purines or N1 of pyrimidines.[1] The nitrogenous bases are heterocyclic compounds classified as purines (adenine and guanine) or pyrimidines (cytosine, thymine in DNA, or uracil in RNA), which provide the functional diversity essential for biological roles.[1] Nucleosides serve as the fundamental building blocks of nucleic acids, forming nucleotides when phosphorylated, and play critical roles in storing and transmitting genetic information, as well as in cellular processes like replication, transcription, and translation.[2] In DNA, deoxyribonucleosides predominate, while ribonucleosides are key to RNA, enabling the synthesis of proteins and regulation of gene expression across all living organisms.[1] Beyond genetics, nucleosides and their analogs have significant applications in medicine, acting as antiviral and anticancer agents by interfering with nucleic acid synthesis in pathogens or rapidly dividing cells.[2]
Overview
Definition
A nucleoside is defined as a glycosylamine molecule composed of a nitrogenous nucleobase—either a purine (such as adenine or guanine) or a pyrimidine (such as cytosine, thymine, or uracil)—covalently linked to a five-carbon sugar, specifically ribose or 2'-deoxyribose, via a β-N-glycosidic bond.[3] This bond forms between the anomeric carbon (C1') of the sugar and the nitrogen atom of the nucleobase (N9 for purines or N1 for pyrimidines), resulting in a structure that serves as a fundamental building block in biological systems.[4] The general formula can be represented conceptually as nucleobase–sugar, emphasizing the absence of additional phosphate groups that characterize related compounds.In contrast to nucleotides, which are the phosphorylated derivatives of nucleosides, nucleosides lack the phosphate moiety esterified to the 5'-hydroxyl group of the sugar.[1] This distinction is critical, as the addition of one to three phosphate groups in nucleotides enables their roles in energy transfer, signaling, and polymerization into nucleic acids, whereas nucleosides primarily function in their unphosphorylated form in certain metabolic pathways.[5]The historical foundation of nucleoside research traces back to the late 19th century, when Albrecht Kossel isolated key components of yeast nucleic acid in 1885, including purine bases like adenine and guanine through hydrolysis.[6] Building on this, adenosine was isolated as an example of a pure nucleoside in 1909 through the work of Phoebus A. Levene and Walter A. Jacobs from yeast RNA.[7] Levene coined the term "nucleoside" that same year to describe these base-sugar conjugates, distinguishing them from the newly termed "nucleotides" introduced in 1908.[8]
Chemical Structure
A nucleoside consists of a nitrogenous base covalently linked to a pentose sugar through a glycosidic bond. The nitrogenous bases are divided into two classes: purines, which are adenine and guanine featuring a fused pyrimidine-imidazole ring system, and pyrimidines, including cytosine, thymine, and uracil, each with a single six-membered heterocyclic ring containing two nitrogens.[9] The pentose sugar is either D-ribose, characterized by hydroxyl groups at the 2', 3', and 5' positions, or 2'-deoxy-D-ribose, which lacks the 2'-hydroxyl group and has a hydrogen atom in its place; both sugars exist in the furanose (five-membered ring) form in nucleosides.[4][3]The linkage between the base and sugar is a β-N-glycosidic bond, formed by the anomeric C1' carbon of the sugar and a specific nitrogen atom on the base. In purines, the bond attaches to the N9 position, while in pyrimidines, it connects to the N1 position.[9][4] The β stereochemistry orients the base above the plane of the sugar ring, which is critical for enzymatic recognition and incorporation into biological polymers, as the α-anomer (base below the plane) is not naturally utilized in cellular processes.[10][3]Key structural features include standardized atom numbering to facilitate nomenclature and analysis. Purine bases are numbered 1 through 9, with nitrogens at positions 1, 3, 7, and 9; pyrimidine bases use numbers 1 through 6, with nitrogens at 1 and 3. Sugar atoms are distinguished by prime notation: the ring comprises C1' (anomeric, attached to the base), C2', C3', C4', and the ring oxygen between C4' and C1', with C5' bearing a hydroxymethyl group (-CH₂OH). In ribonucleosides, the presence of the 2'-hydroxyl group, along with those at 3' and 5', imparts distinct reactivity and conformational properties compared to deoxyribonucleosides.[4][9]Adenosine serves as a prototypical example of a ribonucleoside structure. It features the purine base adenine (6-aminopurine) bonded via the β-N9 glycosidic linkage to the C1' of β-D-ribofuranose. In standard textual or schematic representations, the adenine's double-ring system is depicted horizontally to the left, connected at its N9 to the upper right of the furanose ring (C1'), with the ribose showing the 2'-OH group projecting downward (endo or exo conformation depending on puckering), the 3'-OH upward, and the 5'-CH₂OH extending to the right or bottom; this arrangement emphasizes the four chiral centers at C1', C2', C3', and C4' of the sugar.[9]
Classification
Ribonucleosides
Ribonucleosides are a class of nucleosides composed of a nitrogenous base linked to a D-ribose sugar molecule, distinguished by the presence of a hydroxyl group (-OH) at the 2' position of the ribose ring. This structural feature arises from the β-N-glycosidic bond connecting the base's nitrogen (N9 for purines or N1 for pyrimidines) to the C1' anomeric carbon of the ribose, forming the core unit of ribonucleic acid (RNA). Unlike deoxyribonucleosides, the 2'-OH imparts unique chemical and conformational properties to ribonucleosides, influencing their role in RNA structure and function.[11]The four canonical ribonucleosides are adenosine, guanosine, cytidine, and uridine, each derived from one of the primary RNA nucleobases and abbreviated as A, G, C, and U, respectively. Adenosine, formed from adenine (a purine base), participates in base pairing with uridine through two hydrogen bonds, stabilizing RNA secondary structures like helices. Guanosine, derived from guanine (another purine), forms three hydrogen bonds with cytidine, contributing to the strong G-C pairs essential for RNA stability. Cytidine, based on cytosine (a pyrimidine), pairs with guanosine to enable Watson-Crick base pairing in RNA. Uridine, linked to uracil (a pyrimidine), complements adenosine via two hydrogen bonds, replacing thymine found in DNA contexts.[11][12]Ribonucleosides exhibit higher chemical reactivity compared to their deoxy counterparts, primarily due to the 2'-OH group, which facilitates nucleophilic attacks and renders RNA polymers susceptible to alkaline hydrolysis. This 2'-OH enables intramolecular participation in phosphodiester bond cleavage under basic conditions, where deprotonation of the hydroxyl promotes a 2',3'-cyclic phosphate intermediate, leading to strand breakage—a property exploited in RNA sequencing and purification techniques. Additionally, the ribose sugar in ribonucleosides preferentially adopts a C3'-endo pucker conformation, driven by the 2'-OH's stereoelectronic effects, which favors the A-form helical geometry in RNA and contrasts with the C2'-endo pucker of deoxyribose that supports the more stable B-form in DNA; this puckering difference contributes to RNA's relative instability and flexibility in biological contexts.[13][14]
Deoxyribonucleosides are nucleosides consisting of a nitrogenous base—either a purine (adenine or guanine) or a pyrimidine (cytosine or thymine)—glycosidically linked to 2'-deoxy-D-ribose, a pentosesugar lacking a hydroxyl group at the 2' position.[18] This structural difference from ribonucleosides, which feature ribose with a 2'-OH group, enhances the stability of deoxyribonucleosides against base-catalyzed hydrolysis.[19]The four canonical deoxyribonucleosides found in DNA are deoxyadenosine, deoxyguanosine, deoxycytidine, and thymidine. Thymidine is unique among these, as its base, thymine, is a methylated form of uracil (5-methyluracil), which provides additional protection against spontaneous deamination compared to cytosine.[20]
These formulas are derived from structural data for the β-D-anomers predominant in biological systems.[18][21][22][23]Deoxyribonucleosides exhibit increased chemical stability relative to ribonucleosides due to the absence of the 2'-OH group, which prevents nucleophilic attack leading to strand cleavage in alkaline conditions. In DNA, the deoxyribose sugar typically adopts a C2'-endo puckering conformation, contributing to the B-form helix's characteristic wide major groove and overall rigidity.[19][24]Deoxyribonucleosides are primarily generated through enzymatic reduction of ribonucleotides by ribonucleotide reductase, which removes the 2'-OH equivalent to produce deoxyribonucleotides; these are then dephosphorylated to yield the free nucleosides.[25]
Modified Nucleosides
Modified nucleosides are chemically altered versions of the canonical ribonucleosides—adenosine, guanosine, cytidine, and uridine—through post-transcriptional modifications that introduce diverse chemical groups, such as methylations or acetylations, to the base or sugar moieties.[26] These alterations expand the functional repertoire of RNA beyond the standard forms, enabling specialized roles in cellular processes.[26]Key examples of modified nucleosides include inosine, which is produced by deamination of adenosine at the C6 position of the purine ring, resulting in a hypoxanthine base that facilitates wobble base pairing in tRNA anticodons.[26]Pseudouridine, an isomer of uridine, features a carbon-carbon glycosidic bond between the uracil base and the ribose sugar at the C5 position instead of the typical nitrogen-carbon linkage, enhancing RNA structural stability through additional hydrogen bonding.[26] Wybutosine is a hypermodified guanosine derivative forming a tricyclic structure with a large fluorescent side chain attached at position 37 of tRNA, which strengthens codon-anticodon interactions during translation.[26] Other prominent examples are N6-methyladenosine, involving methylation at the N6 amino group of adenosine to modulate mRNA dynamics, and 5-methylcytidine, where a methyl group is added to the C5 position of cytidine for improved base stacking in RNA helices.[26]Over 170 distinct types of modified nucleosides have been identified across various RNA species, reflecting their extensive diversity.[27] These modifications occur predominantly in transfer RNA (tRNA), where they exhibit the greatest structural variety to fine-tune translation fidelity; ribosomal RNA (rRNA), aiding in ribosome assembly and function; and messenger RNA (mRNA), influencing processing and localization.[26] Their presence across all domains of life underscores an evolutionary significance, likely tracing back to the RNA world hypothesis, where such changes enhanced RNA stability and adaptability.[26]In preview, these modifications often improve RNA stability, alter recognition by proteins, or refine base-pairing specificity, with deeper roles explored in metabolic and signaling contexts.[26]
Biological Functions
Role in Nucleic Acids
Nucleosides serve as the foundational units for nucleic acids by first undergoing phosphorylation to form nucleotides, which are the activated monomers incorporated into DNA and RNA chains. This phosphorylation adds one or more phosphate groups to the 5' hydroxyl of the ribose or deoxyribose sugar, enabling the nucleotides to participate in polymerization reactions catalyzed by enzymes such as DNA polymerase and RNA polymerase.[28]The polymerization process links nucleotides via 3'-5' phosphodiester bonds, where the 5' phosphate of one nucleotide condenses with the 3' hydroxyl of the adjacent nucleotide, forming the sugar-phosphate backbone of the nucleic acid strand. This condensation reaction is reversible through hydrolysis and can be represented by the simplified equation:n \text{ Nucleotide} \rightarrow (\text{Nucleotide})_n + (n-1) \text{H}_2\text{O}The resulting polynucleotide chains store genetic information through the sequence of their nitrogenous bases.[29][30]In DNA, deoxyribonucleosides—2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine, and thymidine—are phosphorylated to deoxyribonucleotides that polymerize into two antiparallel strands forming a right-handed double helix. The stability of this structure arises from complementary base pairing between the strands: adenine (A) pairs with thymine (T) through two hydrogen bonds, while guanine (G) pairs with cytosine (C) through three hydrogen bonds, ensuring specific and faithful replication of genetic material.[31][32]In RNA, ribonucleosides—adenosine, guanosine, cytidine, and uridine—are similarly phosphorylated to ribonucleotides that typically form single-stranded polymers capable of folding into intricate secondary and tertiary structures via intramolecular base pairing and other interactions. Here, uracil (U) substitutes for thymine and pairs with adenine through two hydrogen bonds, facilitating diverse functional roles such as messenger RNA in protein synthesis and catalytic ribozymes.[11][33]
Metabolic and Signaling Roles
Nucleosides play essential roles in cellular energymetabolism, primarily through adenosine, which is integral to the adenosine triphosphate (ATP) and adenosine diphosphate (ADP) cycle. ATP serves as the universal energy currency, transferring phosphate groups to drive endergonic reactions, while hydrolysis to ADP and inorganic phosphate releases energy for cellular processes. Adenosine is liberated during ATP catabolism and can be reincorporated into nucleotides, maintaining energy homeostasis across tissues. Additionally, ATP is converted to cyclic adenosine monophosphate (cAMP) by adenylate cyclase, acting as a key second messenger in signal transduction pathways that regulate glycogenolysis, hormone secretion, and ion channel activity.[34][35]In nucleotide metabolism, salvage pathways enable the recycling of free nucleosides to prevent wasteful de novo synthesis and conserve energy. Nucleoside kinases, such as adenosine kinase and deoxyguanosine kinase, catalyze the initial phosphorylation of nucleosides like adenosine and deoxyguanosine to their monophosphate forms using ATP, followed by further phosphorylation to di- and triphosphates. These pathways are particularly vital in tissues with high nucleotide turnover, such as bone marrow and brain, where they support hematopoiesis and neurotransmitter synthesis by linking nucleoside availability to replication stress responses. Defects in these kinases can disrupt nucleotide pools, highlighting their regulatory importance.[36][37]Nucleosides also function as extracellular signaling molecules, with adenosine acting as a neuromodulator by binding to G-protein-coupled receptors. Activation of A1 receptors inhibits adenylyl cyclase and reduces neurotransmitter release, promoting neuronal hyperpolarization and neuroprotection in conditions like epilepsy. In contrast, A2A and A2B receptors stimulate adenylyl cyclase, increasing cAMP to enhance vasodilation and immune suppression. Adenosine's anti-inflammatory effects, mediated primarily through A2A receptors on immune cells, attenuate cytokine production and neutrophil activation during tissue injury or ischemia, thereby resolving inflammation.[38][39][40]Modified nucleosides contribute to signaling and structural stability in biological molecules. Pseudouridine, formed by isomerization of uridine in RNA, enhances thermodynamic stability through an additional hydrogen bond, facilitating proper folding of transfer RNAs and ribosomal RNAs essential for translation efficiency. Inosine, a deaminated form of adenosine, serves as an agonist for A3 receptors on immune cells, modulating mast cell degranulation and suppressing allergic responses by inhibiting pro-inflammatory cytokine release. These modifications fine-tune RNA function and immune regulation without altering genetic coding.[41][42][43]Disruptions in nucleoside metabolism lead to severe disorders, underscoring their physiological significance. Adenosine deaminase deficiency causes accumulation of toxic deoxyadenosine metabolites, depleting lymphocytes and resulting in severe combined immunodeficiency (SCID), characterized by recurrent infections and impaired adaptive immunity. Similarly, deficiencies in purine salvage enzymes like hypoxanthine-guanine phosphoribosyltransferase (HPRT) impair nucleobase recycling, elevating de novo purine synthesis and uric acid levels, which precipitate gout through crystal-induced inflammation in joints. These conditions illustrate how nucleoside pathways intersect metabolism and immunity.[44][45]
Synthesis and Occurrence
Biosynthesis
Nucleosides are synthesized in living organisms primarily through de novo and salvage pathways, which produce nucleotide intermediates that are subsequently dephosphorylated to yield free nucleosides. The de novo pathway constructs the purine or pyrimidine ring from simple precursors like amino acids, CO₂, and one-carbon units, while the salvage pathway recycles free bases and ribose derivatives to conserve energy. These processes occur in the cytoplasm (and sometimes mitochondria or chloroplasts in plants), ensuring a supply of nucleosides for nucleic acid synthesis, energy transfer, and signaling.[46]In de novo purine nucleoside biosynthesis, the pathway initiates with 5-phosphoribosyl-1-pyrophosphate (PRPP) reacting with glutamine to form 5-phosphoribosylamine, catalyzed by amidophosphoribosyltransferase, the committed step. This is followed by more than 10 additional enzymatic reactions incorporating glycine, formate, aspartate, and CO₂ to assemble inosine monophosphate (IMP), a key intermediate. IMP is then converted to adenosine monophosphate (AMP) via adenylosuccinate synthase and lyase, or to guanosine monophosphate (GMP) via IMP dehydrogenase and GMP synthase. The resulting ribonucleotides are dephosphorylated by 5'-nucleotidases to produce ribonucleosides like adenosine and guanosine. This pathway is energetically costly, consuming six high-energy phosphate bonds per purine nucleotide.[47][48]De novo pyrimidine nucleoside biosynthesis begins with the formation of carbamoyl phosphate from glutamine, CO₂, and ATP, catalyzed by carbamoyl phosphate synthetase II. This reacts with aspartate via aspartate transcarbamoylase to form carbamoylaspartate, followed by ring closure and decarboxylation to orotate, and finally orotate phosphoribosyltransferase couples orotate with PRPP to yield uridine monophosphate (UMP). UMP is converted to cytidine monophosphate (CMP) by CTP synthetase. Dephosphorylation produces uridine and cytidine. The pathway involves six main steps and is more streamlined than purine synthesis.[49][50]The salvage pathway provides an efficient alternative by recycling purine and pyrimidine bases or nucleosides, often using less energy. Nucleoside phosphorylases facilitate the direct formation of nucleosides from free bases and ribose-1-phosphate (derived from nucleotide degradation or glycolysis). For purines, purine nucleoside phosphorylase (PNP) catalyzes the reversible phosphorolysis:\text{hypoxanthine} + \alpha\text{-D-ribose-1-phosphate} \rightleftharpoons \text{inosine} + \text{P}_\text{i}Similar reactions occur for guanine to guanosine and pyrimidines via uridine phosphorylase (for uracil to uridine) or thymidine phosphorylase (for thymine to thymidine). Bases can also be salvaged to nucleotides via phosphoribosyltransferases like hypoxanthine-guanine phosphoribosyltransferase (HGPRT) or adenine phosphoribosyltransferase (APRT), followed by dephosphorylation. Adenosine kinase phosphorylates free adenosine to AMP. This pathway is crucial in tissues with high nucleotide turnover, such as the liver and brain.[46]Deoxyribonucleosides are primarily generated from ribonucleotides via ribonucleotide reductase (RNR), which reduces NDPs to dNDPs in a radical-based mechanism requiring thioredoxin or glutaredoxin as cofactors. The dNDPs are phosphorylated to dNTPs and dephosphorylated as needed to form deoxyadenosine, deoxyguanosine, deoxyuridine, or deoxythymidine. RNR is allosterically regulated to balance dNTP pools.[51]Both de novo and salvage pathways are tightly regulated by feedback inhibition to prevent overproduction. In purine synthesis, AMP and GMP allosterically inhibit amidophosphoribosyltransferase and the IMP branch-point enzymes. Pyrimidine synthesis is inhibited by UTP at carbamoyl phosphate synthetase II. RNR activity is controlled by dNTPs, with dATP inhibiting overall reduction and activating CDP reduction for balanced DNA precursor supply. These mechanisms ensure nucleoside homeostasis across cell types and physiological states.[46][49][51]
Prebiotic Synthesis
The prebiotic synthesis of nucleosides presents significant challenges due to the inherent instability of both nucleobases and sugars under early Earth conditions, where aqueous environments promote rapid degradation, and the formation of the N-glycosidic bond requires high selectivity to favor the β-anomer and correct regiochemistry over competing reactions.[52]Ribose, in particular, is prone to epimerization and decomposition, while free nucleobases can undergo hydrolysis or side reactions, complicating the coupling process known as glycosylation.[53] These obstacles have long hindered models of abiotic nucleoside formation, necessitating pathways that avoid free sugars or bases to achieve viable yields.Early experimental efforts in the 1980s, led by Leslie Orgel, explored UV-irradiated mixtures of purine precursors and ribose to mimic interstellar or atmospheric chemistry, demonstrating the formation of purine ribonucleosides like adenosine through photochemical activation, albeit with low efficiency due to non-selective bond formation.[54] A breakthrough came in 2009 with Powner et al.'s discovery of a pathway involving 2-aminooxazole intermediates, which reacts with ribose under plausible prebiotic wet-dry cycles to selectively produce pyrimidine ribonucleotides, bypassing the instability of free pyrimidines and enabling the synthesis of cytidine and uridine precursors without enzymatic intervention.More recent advances have built on these foundations, with Becker et al. (2019) reporting a unified route using the two-carbon unit cyanoacetylene combined with sugars in wet-dry cycles, yielding both pyrimidine and purine ribonucleosides with high regioselectivity and up to several percent efficiency, directly addressing glycosylation challenges.[55] Studies have highlighted the role of mineralcatalysis, such as metal-doped montmorillonite clays, in facilitating nucleoside and nucleotide synthesis by adsorbing reactants and promoting dehydration under mild conditions, enhancing yields in simulated hydrothermal environments.[56] These ribonucleoside-focused pathways, particularly for adenosine and uridine precursors, achieve efficiencies of approximately 1-10% in laboratory simulations, providing a robust chemical basis for the emergence of RNA.[57] As of 2025, further progress includes atomic-level insights into nanoclay minerals like kaolinite promoting nucleoside phosphorylation and the role of N-O bond-containing compounds as feedstocks in prebiotic metabolism.[58][59]Such abiotic syntheses support the RNA world hypothesis by enabling the pre-RNA accumulation of nucleosides capable of self-replication and polymerization without biological catalysts, bridging simple prebiotic molecules to complex genetic systems.[52]
Natural Sources
Nucleosides enter human diets primarily through the consumption of foods containing nucleic acids, which are degraded by digestive nucleases into nucleotides and then further broken down into nucleosides by nucleotidases and phosphatases in the gastrointestinal tract. Rich sources include organ meats such as liver and kidney, seafood like fish and shellfish, legumes including beans and lentils, and fermented products like beer derived from yeast. Vegetables and mushrooms also contribute smaller amounts, with overall dietary nucleic acid content varying based on meal composition.[60][61][62]The typical daily human intake of nucleosides from diet ranges from 0.5 to 2 grams, depending on consumption of high-nucleic-acid foods, providing a significant exogenous supply that supplements endogenous biosynthesis.[63][61] This intake supports metabolic demands, particularly during periods of rapid growth or stress, without requiring de novo synthesis for all needs.In microbial systems, nucleosides are produced and extracted from RNA-abundant organisms like yeast (e.g., Saccharomyces cerevisiae) and certain bacteria through fermentation processes, yielding RNA-rich biomass that serves as a natural source. These microbial extracts, often from brewer's or baker's yeast, are processed to release nucleosides for nutritional or research use, offering a scalable alternative to direct dietary acquisition.[64][65]Environmentally, nucleosides occur in oceans and seawater as components of dissolved organic matter, released from the decay of biomass such as phytoplankton, bacteria, and other marine organisms, and they participate in broader geochemical cycles involving carbon, nitrogen, and phosphorusrecycling. These concentrations are low, reflecting rapid microbial uptake and transformation.[66][67][68]Extraction of nucleosides from natural sources commonly employs enzymatic hydrolysis: nucleic acids are first cleaved by phosphodiesterases into nucleotides, followed by treatment with phosphatases to remove phosphate groups and nucleosidases to yield free nucleosides, achieving purities exceeding 95% for research and pharmaceutical applications after chromatographic purification. This method is particularly effective for yeast-derived RNA, minimizing chemical degradation and preserving bioactivity.[69][70][71]
Applications
In Medicine
Nucleoside analogues play a central role in antiviral therapy, primarily by mimicking natural nucleosides to interfere with viral replication. Acyclovir, a guanosine analogue, is widely used to treat herpes simplex virus (HSV) infections, including genital herpes and herpes zoster, through selective phosphorylation by viral thymidine kinase and subsequent inhibition of viral DNA polymerase, resulting in chain termination of viral DNA synthesis.[72][73] Similarly, zidovudine (AZT), a thymidine analogue, was the first approved drug for HIV treatment, acting as a chain terminator by incorporating into viral DNA via reverse transcriptase, halting elongation due to the absence of a 3'-hydroxyl group.[74][75]In anticancer applications, nucleoside analogues target rapidly dividing malignant cells by disrupting DNA synthesis. Cytarabine, a cytidine analogue, is a cornerstone in acute myeloid leukemia treatment, where it is converted to cytarabine triphosphate (ara-CTP) and incorporated into DNA, causing chain termination and inhibition of DNA polymerase.[76][77]Gemcitabine, another cytidine analogue with 2',2'-difluorodeoxycytidine structure, is standard for advanced pancreatic cancer, exerting cytotoxicity through incorporation into DNA and RNA, leading to masked chain termination and depletion of deoxyribonucleotide pools.[78][79]Beyond antivirals and anticancer agents, nucleosides and their analogues address other conditions. Adenosine, a natural purine nucleoside, is administered intravenously to terminate paroxysmal supraventricular tachycardia by transiently blocking atrioventricular nodal conduction.[80]Cladribine, a chlorinated deoxyadenosine analogue, is approved for relapsing multiple sclerosis, selectively depleting lymphocytes through accumulation of toxic metabolites that induce apoptosis in B and T cells.[81]Nucleoside analogues are structurally modified—often in the sugar moiety (e.g., acyclic chain in acyclovir, 3'-azido in AZT, arabinose configuration in cytarabine, difluoro substitution in gemcitabine) or base—to resist enzymatic degradation by nucleases or phosphorylases, enhancing bioavailability and duration of action.[82] However, these agents commonly cause myelosuppression, manifesting as neutropenia, thrombocytopenia, and anemia, due to interference with bone marrowprogenitor cell proliferation; this is particularly pronounced with prolonged use of AZT, cytarabine, and gemcitabine.[82]Recent advancements leverage modified nucleosides in mRNA-based therapeutics, notably in 2024-2025 COVID-19 vaccine boosters incorporating N1-methylpseudouridine to substitute uridine, thereby reducing innate immune activation and immunogenicity while boosting translation efficiency and stability.[83][84]
In Biotechnology and Technology
Nucleosides play a pivotal role in biotechnology through their derivatives, such as dideoxynucleoside triphosphates (ddNTPs), which enable chain-termination sequencing in the Sanger method. Developed in 1977, this technique relies on DNA polymerase incorporating fluorescently or radioactively labeled ddNTPs alongside normal deoxynucleoside triphosphates (dNTPs) during primer extension, causing random termination at each nucleotide position to generate fragments for electrophoretic separation and sequence readout.[85] The method's precision has made it a gold standard for validating next-generation sequencing results and targeted amplicon analysis, with ongoing adaptations incorporating capillary electrophoresis for higher throughput.[86]In nucleic acid amplification and synthesis, deoxynucleoside triphosphates (dNTPs) serve as essential substrates for DNA polymerases in polymerase chain reaction (PCR), providing the building blocks for exponential amplification of specific DNA sequences. Introduced in 1988, PCR uses thermostable Taq polymerase to cycle through denaturation, annealing, and extension phases, incorporating dATP, dCTP, dGTP, and dTTP to synthesize billions of copies from minimal template DNA.[87] Modified nucleosides enhance these processes; for instance, locked nucleic acids (LNAs), featuring a methylene bridge constraining the ribose ring into a C3'-endo conformation, increase the thermal stability of oligonucleotide probes by up to 10°C per substitution, improving specificity in qPCR and in situ hybridization assays.[88] LNAs enable shorter, more discriminatory probes for detecting single nucleotide polymorphisms or microRNAs without compromising bindingaffinity.[89]Reverse transcriptase enzymes facilitate the conversion of RNA to complementary DNA (cDNA), utilizing ribonucleoside-containing RNA templates to synthesize first-strand cDNA with dNTP substrates, a cornerstone for studying gene expression via RNA-seq and RT-PCR. These viral-derived enzymes, such as M-MLV reverse transcriptase, process diverse RNA templates including mRNA and viral genomes, enabling downstream applications like cloning and functional genomics.[90]In nanotechnology, nucleoside derivatives form the basis of advanced materials and sensors. Nucleoside-based supramolecular hydrogels, self-assembled through hydrogen bonding and π-π stacking of purine or pyrimidine bases, exhibit biocompatibility and shear-thinning properties ideal for 3D bioprinting and drug encapsulation, with guanosine derivatives forming stable nanofiber networks at concentrations as low as 0.5% w/v.[91] Nucleic acid aptamers, short single-stranded DNA or RNA sequences incorporating standard nucleosides, fold into three-dimensional structures for high-affinity target recognition in biosensors, detecting biomolecules like thrombin or pathogens with dissociation constants in the nanomolar range and enabling label-free electrochemical or fluorescent readouts.[92] Phosphorothioate modifications, replacing non-bridging oxygen with sulfur in the phosphate backbone, confer nuclease resistance to these aptamers and hydrogels, extending their half-life in biological media by 10- to 100-fold while maintaining hybridization properties.[93]Industrially, enzymatic production of nucleosides leverages nucleoside phosphorylases for scalable synthesis of natural and modified variants used in dietary supplements, such as inosine and cytidine for cognitive and energy support. These biocatalysts, like purine nucleoside phosphorylase, catalyze transglycosylation reactions in multi-enzyme cascades, achieving yields over 90% under mild conditions and reducing waste compared to chemical routes.[94] Recent advances in synthetic biology, including engineered de novo pathways in microbial hosts, enable custom nucleoside analogs by 2025, with cell-free systems incorporating non-canonical bases for expanded genetic codes and novel therapeutics, boosting production efficiency by integrating metabolic engineering with directed evolution.[95]